51��Ƶ

A new study in JAMA Network Open shows that availability of the two-dose Jynneos vaccine to protect against mpox was not widespread during last summer's outbreak, with only 17.1% of the US population living within 15 minutes of a vaccination site and 50% living more than an hour away. (Soucheray, 4/11)

An analysis of prominent probiotic bacteria strains isolated from food and probiotic dietary supplements found the presence of several antibiotic resistance genes (ARGs), Hungarian researchers reported yesterday in Eurosurveillance. (Dall, 4/7)

Atopic dermatitis and psoriasis are well-established battlefields for anti-inflammatory biologic drugs. Now, two drugmakers are preparing to launch products in a lesser-known disease area with significant unmet medical need: hidradenitis suppurativa (HS). (Liu, 4/10)

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study. If confirmed in additional studies, enoblituzumab could become the first promising antibody-based immunotherapy agent against prostate cancer. (John Hopkins Medicine, 4/10)

U.S. neurologists are “cautiously optimistic” about using Eisai’s Leqembi in Alzheimer’s disease as concerns about safety and the need for the FDA’s full green light for the drug remain high barriers to uptake. (Adams, 4/11)

AbbVie Inc and partner Johnson & Johnson intend to voluntarily withdraw the accelerated approvals of their Imbruvica drug in the U.S. for patients with certain types of blood cancer, the companies said on Thursday. (4/6)

Respiratory syncytial virus (RSV) infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein–based (RSVpreF) vaccine in this population are unknown. (Walsh, M.D., et al, 4/5)